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ABSTRACT:  Carbamazepine (CBZ) is an effective antiepileptic drug that has been associated with 
hypersensitivity reactions. The pathogenesis of those reactions is incompletely understood but is postulated 
to involve a complex interplay between the drug’s metabolism, genetic variation in human leukocyte 
antigens and adverse activation of the immune system. Multiple T-cell activation mechanisms have been 
hypothesised, including activation by drug-peptide conjugates derived from proteins haptenated by reactive 
metabolites. However, definitive evidence of the drug-protein adducts in patients has been lacking. In this 
study, mass spectrometry was used to characterize protein modifications by microsomally generated 
metabolites of CBZ and in patients taking CBZ therapy. CBZ 10,11-epoxide (CBZE), a major electrophilic 
plasma metabolite of CBZ, formed adducts with glutathione-S-transferase pi (GSTP; Cys47) and human 
serum albumin (HSA; His146 and His338, but not Cys34) in vitro, via notably divergent side-chain 
selectivity. Both proteins were adducted at the same residues by undefined monoxygenated metabolites 
([O]CBZ) when they were incubated with human liver microsomes, NADPH and CBZ. There was also 
evidence for formation of a CBZ adduct at His146 and His338 of HSA derived via dehydration from an 
intermediate arene oxide adduct. Glutathione trapping of reactive metabolites confirmed microsomal 
production of CBZE, and indicated simultaneous production of arene oxides. In 15 patients prescribed CBZ 
therapy, [O]CBZ-modified HSA (His146) was detected in all the subjects. The relative amount of adduct 
was moderately positively correlated with plasma concentrations of CBZ (r2 = 0.44, p = 0.002) and CBZE 
(r2 = 0.35, p = 0.006). Our results have provided the first chemical evidence for microsomal production of 
[O]CBZ species that are able to escape the microsomal domain to react covalently with soluble proteins. 
This study has also demonstrated the presence of circulating [O]CBZ-modified HSA in patients without 
hypersensitivity reactions who were receiving standard CBZ therapy. The implications of those circulating 
adducts for susceptibility to CBZ hypersensitivity merits further immunological investigation in 
hypersensitive patients.  
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INTRODUCTION 
Carbamazepine (CBZ) is an effective treatment for epilepsy but up to 10% of patients experience a 
hypersensitivity reaction.1 Those reactions can range from mild to severe life-threatening conditions.2 The 
reactions principally involve the skin but can also include other organs such as the liver and kidneys.2 The 
pathophysiology of hypersensitivity to CBZ is incompletely understood but has been hypothesised to 
involve a complex interplay between the drug’s metabolism, genetic variation in human leukocyte antigens 
(HLA) and activation of the immune system.  
 
The clinical features of CBZ hypersensitivity in conjunction with the identification of CBZ-specific T cells 
from patients with a history of hypersensitivity to CBZ confirms an immunological aetiology.3 Increased 
susceptibility to CBZ-induced reactions has been observed in patients of South-East Asian origin who 
possess HLA-B*15:02.4 HLA alleles encode the major histocompatibility complex (MHC), which presents 
protein-derived peptides to T cells as part of the adaptive immune response. MHC class I molecules are 
encoded by HLA-A, HLA-B and HLA-C whilst MHC class II molecules are encoded by HLA-DR, HLA-DQ 
and HLA-DP.5 In other ethnicities, HLA-A*31:01 has been significantly associated with increased risk for 
multiple phenotypes of CBZ-induced cutaneous hypersensitivity.6, 7 Functional studies investigating the 
pathomechanisms of CBZ hypersensitivity using T cell clones generated from hypersensitive patients 
support direct activation of  T cells by CBZ, via ligand binding, i.e. a pharmacological interaction (PI) 
mechanism.3, 8, 9 Further studies have claimed that HLA-B*15:02 on antigen presenting cells presents CBZ 
directly to specific T-cell receptors (TCR), thereby activating a cytotoxic immune response.10, 11 Structural 
modelling of the HLA-B*15:02/peptide/CBZ/TCR complex revealed the CBZ molecule to be located at the 
interface between HLA-B*15:02/peptide and TCR with CBZ having higher affinity for TCR over HLA-
B*15:02/peptide.12 The authors postulate two hypotheses: (i) the presence of specific TCR subtypes 
increases interaction between TCR/CBZ and HLA-B*15:02/peptide complex leading to activation of the 
immune system; and (ii) binding of CBZ to TCR shifts the receptor’s specificity and thereby the CBZ-
modified TCR is able to recognise self-peptides presented by HLA-B*15:02, causing an autoimmune 
reaction. Finally, the major electrophilic metabolite of CBZ, carbamazepine 10,11-epoxide (CBZE), is also 
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able to bind HLA-B*15:02 in vitro, raising the possibility that CBZE may be the responsible immunogen in 
CBZ hypersensitivity.13  
 
The metabolism of CBZ in humans is complex, yielding more than 30 metabolites.14  Bioactivation of CBZ 
by P450 in human liver microsomes was revealed by the formation of protein-reactive metabolites.15, 16 The 
reactive species were not identified but from their deactivation by glutathione (GSH) were evidently soft 
electrophiles.15 It has been hypothesised that multiple reactive intermediates of CBZ, such as arene oxides,15, 
17, 18 9-acridine carboxaldehyde,19 iminostilbene,20, 21 an o-quinone22 and CBZE,21 are responsible for the 
protein adduct formation (Scheme 1). Importantly, CBZE, an abundant23 and pharmacologically active 
plasma metabolite24 formerly believed to be chemically stable, has been demonstrated to be reactive through 
the spontaneous formation of two isomeric CBZE-glutathione adducts in vitro (CBZE-SG1 and CBZE-SG2) 
and its covalent binding to human liver microsomes.25 However, with the exceptions of CYP1A226 and 
CYP3A427, none of the microsomal proteins that form covalent adducts with the reactive metabolites of 
CBZ has been identified. Molecular modelling alone has suggested Cys239 of CYP3A4 could be a 
haptenation site,27 creating a thioether antigen to which the immune response may be directed.28 That 
deduction, the reaction of CBZE with GSH,25 and the trapping of CBZ’s reactive metabolites by GSH in 
microsomal incubations29 predict modification of proteins at cysteine residues.  The inferred structures of 
the multiple GSH adducts produced from CBZ by human liver microsomes included thioether derivatives of 
one or more arene oxides, namely products of nucleophilic conjugate addition, as well as the two adducts of 
CBZE.29 Nonetheless CBZE-SG1 and CBZE-SG2 were the most abundant adducts formed from CBZ. 
Consequently, it was hypothesised that CBZE will be the principal protein-adducting metabolite of CBZ.  
 
Although much of the experimental evidence suggests a direct, i.e. PI, mechanism for CBZ hypersensitivity, 
in vitro systems are only able to test the activity of stable and weakly electrophilic candidate antigens; 
highly reactive metabolic intermediate that haptenate proteins cannot be tested equally. It is possible that 
CBZ is able to activate the immune system via multiple mechanisms, including both PI and hapten effects, 
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depending on the metabolic capacity and HLA status of each patient.30 The existence of multiple immune 
activation mechanisms may explain the variation in clinical presentation of CBZ hypersensitivity.  
 
The aims of this study were to characterize the structures of the protein conjugates formed by CBZ’s 
reactive metabolites and hence derive the metabolic pathways of their formation, using HSA and glutathione 
S-transferase pi (GSTP) as model proteins in vitro. GSTP is a proven biochemical reagent for trapping 
highly reactive small-molecule thiophilic electrophiles,31-34 its three nucleophilic cysteines (Cys14, 47 and 
101) exhibiting markedly disparate adduction capabilities.33 HSA has a much more varied set of adductable 
nucleophilic side-chains.35-38 We have previously isolated and identified conjugates of circulating HSA with 
intrinsically reactive drugs,35, 39, 40 circulating reactive drug metabolites36, 41 and metabolic intermediates that 
might be confined to intracellular locations.36, 37 CBZE is an electrophilic species and a major plasma 
metabolite in patients,23 whereas the arene oxides, by analogy with the instability of bromobenzene-3,4-
oxide,42  are likely to be fleeting entities in blood and to react only with cellular proteins. CBZE might 
haptenate HSA in the bloodstream and the protein within hepatocytes that is destined for export. Substantial 
intravascular haptenation by CBZE could manifest itself as an association between the relative abundance of 
[O]CBZ-HSA adducts and plasma concentrations of CBZE. HSA isolated from patients exposed to CBZ 
therapy was analysed to determine if adducts similar to those generated in incubations with human liver 
microsomes could be detected. It is important to characterise the haptenation by CBZ in patients. Conjugates 
of reactive monoxygenated metabolites ([O]CBZ) on HSA and other proteins have the potential to act as 
antigens that trigger the immunological signals responsible for CBZ’s hypersensitivity. 
 
EXPERIMENTAL PROCEDURES 
Chemicals. HSA (97-99% pure) was purchased from Sigma-Aldrich (Poole, Dorset, United 
Kingdom), sequencing-grade modified trypsin from Promega (Southampton, United Kingdom), liquid 
chromatography-mass spectrometry (LC-MS) grade solvents from Fisher Scientific UK Ltd. 
(Loughborough, Leicestershire, United Kingdom), and all other standard reagents from Sigma-Aldrich. CBZ 
and CBZE were purchased from Sigma-Aldrich. Authentic standards of 2-methylcarbamazepine (2-Me-
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CBZ; internal standard), carbamazepine-10,11-trans-dihydrodiol (CBZ-DHD), 2-hydroxycarbamazepine (2-
OH-CBZ) and 3-hydroxycarbamazepine (3-OH-CBZ) were purchased from NewChem Technologies 
(Durham, United Kingdom). The K541 tryptic peptide of HSA (535ATKEQLK541) was synthesised by 
standard solid-phase chemistry and characterized by LC-MS/MS (Figure S1).43  
 
Microsomes and Supersomes. Human liver microsome preparations (UltraPool human liver 
microsomes 150; a pool from 150 mixed gender donors) were obtained from BD Gentest Corp. (Oxford, 
United Kingdom). Microsomes (Supersomes) from baclovirus-infected insect cells expressing human P450 
enzymes (3A4, 2B6, and 2E1) were purchased from BD Gentest Corp. All recombinant enzymes were co-
expressed with human NADPH-cytochrome P450 reductase and human cytochrome b5. 
 
Patients and Volunteers. Single plasma samples were obtained from epilepsy patients attending the 
Walton Centre NHS Foundation Trust, Liverpool. Patient details are listed in Table S1 of the Supporting 
Information. Ethical approval was obtained from the National Research Ethics Service Committee for North 
West – Haydock (ethics reference: 13/NW/0503). Blood samples were collected from fifteen patients who 
had received a stable dose of CBZ for at least six months. The timings of the blood samples relative to the 
last dose of CBZ were recorded.  The blood (5 mL) was collected into lithium heparin-containing tubes and 
was centrifuged at 1500 g and 4oC for 10 min to obtain plasma. Plasma samples were stored in aliquots (0.1 
mL and 0.3 mL) at -80oC until they were taken for assays of CBZ and its metabolites or the isolation of 
HSA. 
Synthesis of the GSH Conjugates of CBZE and the Trapping of Microsomally Generated 
Metabolites of CBZ. The two isomeric GSH conjugates of CBZE (CBZE-SG1 and CBZE-SG2) were 
prepared as authentic metabolite standards by incubating synthetic CBZE (80 μM) with GSH (5 mM) in 
phosphate buffer (0.1 M, pH 7.4; final volume 0.25 mL) at 37oC for 2 h. The reaction mixture was analysed 
without further treatment by LC-MS/MS. Human liver microsomes and Supersomes incubations were 
performed by incubating CBZ (100 μM) with either human liver microsomes (protein concentration, 2 
mg/mL) or Supersomes (P450 concentration, 20 nM), NADPH (2 mM), MgCl2 (5 mM) and GSH (2 mM) 
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for 2 h at 37oC in phosphate buffer (final volume, 0.2 mL). The reactions were started by addition of 
NADPH. Protein concentrations in this and all other experiments were determined by the Bradford assay 
(Sigma-Aldrich). The enzymatic reaction was terminated by addition of two volumes of acetonitrile to the 
reaction mixture. The mixtures were vortexed, and centrifuged at 12,000 g for 5 min at 4oC. The 
supernatants were collected, and evaporated to dryness under nitrogen. These residues were reconstituted in 
0.1% aqueous formic acid (0.5 mL) before analysis by LC-MS/MS as described below.  
 
Analysis of Oxygenated CBZ Metabolites Produced by Microsomes and Recombinant P450 
Enzymes and Characterization of GSH Adducts of CBZ. Reconstituted supernatants from the 
incubations of CBZ with either human liver microsomes or Supersomes were analysed by LC-MS. Aliquots 
(5-20 L) were injected onto a Zorbax Eclipse XDB-C8 column (150  4.6 mm, 5µm; Agilent 
Technologies, Santa Clara, CA) fitted with a Zorbax C18 Reliance pre-column and connected to a 
PerkinElmer series 200 HPLC system (PerkinElmer, Norwalk, CT). Analytes were eluted at room 
temperature with a gradient program of acetonitrile (15% to 33% over 12 min; 33% to 50% over 0.5 min; 
50% for 5.5 min; 50% to 15% over 0.1 min; 15% for 4 min) in ammonium formate (2 mM, pH 3.8) at 1.0 
mL/min. A different eluent was required for analysis of the GSH adducts of CBZ and CBZE, namely a 
gradient of acetonitrile (5% to 30% over 20 min; 30% to 60% over 0.5 min; 60% for 4.5 min; 60% to 5% 
over 0.1 min; 5% for 3.9 min) in 0.05% (v/v) formic acid at 1.0 mL/min. That eluent also resolved the CBZ 
phenols and CBZE. The split-flow to the mass spectrometer was approximately 150 L/min. Metabolites 
were detected in positive-ion mode with a 4000 Qtrap instrument (Sciex, Warrington, United Kingdom) that 
was operated under the following conditions: source temperature, 450 oC; ionspray voltage, 4,500 V; 
desolvation potential, 25 V; Gas-1 and Gas-2 settings, 50; scanning, m/z 100-1,000 over 5 s. Instrument 
management and data processing were accomplished through Analyst 1.5.1 software (Sciex). Analytes were 
identified by chromatographic and mass spectrometric comparisons with authentic standards. Multiple 
reaction monitoring (MRM) transitions for CBZ, its oxygenated metabolites and the GSH adducts are 
specified in Table S2.    
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Modification of His-Tagged GSTP by Synthetic CBZE and Microsomally Generated 
Monoxygenated Metabolites of CBZ. His-tagged human GSTP was expressed in Escherichia coli  as 
described previously.44 Synthetic CBZE was freshly dissolved in methanol (50 mM) and incubated with 
nickel bead-captured GSTP (130 µM), prepared as described by Jenkins et al.,31 in phosphate buffer (0.1 M, 
pH 7.4) at 37oC for 6 h. The molar ratio of CBZE to protein was 10:1. Reactive metabolites were generated 
from CBZ (1 mM) in co-incubations of nickel bead-captured GSTP (40 μM) with either human liver 
microsomes (2 mg/mL) or Supersomes (CYP3A4, CYP2B6 or CYP2E1, 20 nM), MgCl2 (5 mM), and 
phosphate buffer, for 6 h at 37oC. The reactions were started by addition of NADPH (final concentration, 1 
mM). The final volume was 0.4 mL. After the incubation period, a 0.2 mL aliquot was removed from the 
reaction mixture, taking care not to remove any nickel beads, and stored at 4 oC for analysis of CBZ 
metabolite formation (see below). The nickel beads were recovered from the remaining reaction mixture 
using magnetic separation and washed five times with 1 mL phosphate buffer. Ammonium bicarbonate 
solution (50 μL of 50 mM, pH 7.0) was added to the beads and the protein subjected to on-bead tryptic 
digestion (1 μg of trypsin per 200 μg of protein) at 37oC for 16 h. The digest was processed for analysis by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described below.  
 
Concentration-Dependent Modification of HSA by CBZE In Vitro. CBZE freshly dissolved in 
methanol (50 mM) was incubated with HSA (1 mM, 40 µL) in phosphate buffer at 37oC for 16 h. The molar 
ratios of CBZE to protein were 0.1:1, 1:1 and 5:1. The final concentration of methanol ranged between 0.1% 
v/v to 5% v/v. Protein was precipitated twice with nine volumes of ice-cold methanol to remove 
noncovalently bound CBZE, resuspended in 50 µL of phosphate buffer, and then reduced with 10 mM 
dithiothreitol (15 min) and alkylated with 50 mM iodoacetamide (15 min) at room temperature. The protein 
was precipitated once more with methanol and finally dissolved in 50 µL of 50 mM ammonium bicarbonate, 
pH 7.0. The protein (400 µg) was incubated with trypsin (2 µg) overnight at 37oC. Samples of the digest (50 
L) were processed for LC-MS/MS analysis as described below.  
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Time-Dependent Modification of HSA by CBZE in Vitro. CBZE (50 mM) freshly dissolved in 
methanol and diluted in phosphate buffer (1:4, v/v) was incubated with HSA (1 mM, 40 µL) in phosphate 
buffer at 37oC (final CBZE concentration, 5 mM). The final concentration of methanol was 10% (v/v).  
Aliquots of 80 µL were removed after 0.2, 0.5, 1, 3 and 6 h and processed for LC-MS/MS analysis of tryptic 
digests as described above. 
 
Modification of HSA by Microsomally Generated Reactive Metabolites of CBZ. CBZ (50 mM) was 
freshly dissolved in methanol and then diluted 1:5 with phosphate buffer. The CBZ (final concentration, 1 
mM) was co-incubated with either human liver microsomes (2 mg protein/mL) or Supersomes (20 nM 
P450), NADPH (1 mM), MgCl2 (5 mM) and HSA (0.6 mM), in phosphate buffer for 2 h at 37
oC (final 
methanol concentration, 2% v/v). The incubations were then ultra-centrifuged at 105,000 g for 30 min at 
4oC. HSA was recovered from the supernatant by immunoaffinity column chromatography using a 
PerSeptive Biosystems Vision Workstation (Applied Biosystems, Foster City, CA) as described 
previously.41 The HSA was eluted with 12 mM HCl, the eluate neutralized promptly using 1 M Tris buffer 
(pH9), and protein precipitated with nine volumes of ice-cold methanol. The protein was re-suspended in 50 
μL of phosphate buffer and processed for LC-MS/MS as described above. Elution of the HSA conjugates 
under mild conditions - at room temperature, using a low mM acid concentration and relatively brief 
exposure to the eluent – prevented materially significant degradation of the conjugates. 
 
Isolation of HSA from Patients’ Plasma Samples by Resin Binding. Plasma samples (100 μL) 
were thawed at room temperature on the morning of analysis, and HSA was isolated from a 50 μL aliquot 
using a Pierce albumin depletion kit (Thermo Fisher Scientific, Paisley, United Kingdom) according to the 
manufacturer’s instructions. The isolated HSA was reduced with 10 mM dithiothreitol (15 min) before 
alkylation with 50 mM iodoacetamide (15 min) at room temperature. An Amicon Ultra-0.5 mL centrifugal 
filter unit with Ultracel-50 membrane spin columns (Millipore, Watford, United Kingdom) was used to 
concentrate the albumin. The albumin samples were added to the spin column and centrifuged at 9200 g for 
20 min. The columns were then washed with 400 μL of LCMS-grade water at 9200 g for 20 min. LCMS-
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grade water (50 μL) was used to elute the albumin from the spin column. The protein content was 
determined using the Bradford assay. All the albumin solutions were normalised to 100 pmol/μL and 2 μg of 
trypsin was added to each sample before overnight incubation at 37oC (16 h). After trypsin digestion, 
incubations were diluted to 5 pmol/µL in 2% acetonitrile/0.1% formic acid and synthetic K541 tryptic 
peptide of HSA (ATKEQLK) was added as internal loading standard such that its final concentration was 
2.5 pmol/µL. Aliquots were analysed by LC-MS/MS as described below.  
 
Mass Spectrometric Characterisation of Covalently Modified Proteins. In order to characterise 
all potential [O]CBZ- and CBZ-modified peptides, samples of HSA and GSTP tryptic digests were analysed 
firstly using a Triple TOF 5600 instrument (Sciex, Framingham, MA) by previously established methods.38 
Modified peptides were identified by filtering for specific fragment ions in PeakView 1.2.0.3 (Sciex) and 
manual inspection of the spectra. 
Tryptic digests of GSTP and HSA (50 L) were desalted using C18 Zip-Tips (Millipore, Watford, 
United Kingdom) according to the manufacturer’s specifications. Eluates of the samples were dried in a 
rotational vacuum concentrator, and then reconstituted in 2% acetonitrile/0.1% formic acid (v/v). For the 
semi-quantitative analysis of [O]CBZ-modified peptides, aliquots (2.4−5.0 pmol) of the solutions were 
delivered into a QTRAP 5500 (Sciex) ﬁtted with a NanoSpray II source by automated in-line liquid 
chromatography (UltiMate 3000 HPLC System, 5 mm C18 nanoprecolumn and 75 μm × 15 cm C18 
PepMap column; Dionex, Sunnyvale, CA) via a 10-μm inner diameter PicoTip (New Objective, MA). A 
gradient from 2% acetonitrile/0.1% formic acid (v/v) to 50% acetonitrile/0.1% formic acid (v/v) in 60 min 
was applied at a ﬂow rate of 300 nL/min. The ion spray potential was set to 2,200−3,500 V, the nebulizer 
gas to 19, and the interface heater to 150 °C. Spectra were acquired automatically in positive-ion mode using 
information-dependent acquisition powered by Analyst 1.5 software, across mass ranges of 400−1000 amu 
in MS and 100−1000 amu in MS/MS. The five most intense ions in each acquisition were selected for 
MS/MS, using a threshold of 5000 counts per second, with dynamic exclusion for 30 s and rolling collision 
energy.  
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For the MRM detection of drug-modiﬁed peptides, transitions specific for [O]CBZ- and CBZ-
modified tryptic peptides of GSTP and HSA were selected as follows: mass/charge ratio values were 
calculated for all possible peptides containing a histidine, lysine or cysteine residue; to those values were 
added the mass of the proposed hapten (for CBZE and an arene oxide that has not rearomatized after its 
reaction with the protein, 252 amu; for an arene oxide that has rearomatized after its reaction, 234 amu); and 
finally the precursor ion masses were paired with the mass of a fragment ion that was expected to be a 
generic fragment of the predicted adducts, namely the hydroxydibenzoazepinyl species of m/z 210. MRM 
transitions were acquired at unit resolution in both the Q1 and Q3 quadrupoles to maximize specificity. They 
were optimized for collision energy and collision cell exit potential, and the dwell time was 50 ms. MRM 
survey scans were used to trigger enhanced product ion scans of [O]CBZ-modified peptides, with Q1 set to 
unit resolution, dynamic fill selected, and dynamic exclusion for 20 s. Total ion counts were determined 
from a second aliquot of each sample analysed by conventional LC-MS on the same instrument, and were 
used to normalize sample loading on the column. Relative quantification of modified tryptic peptides of 
protein recovered from in vitro incubations was performed by comparing the intensities of the MRM peaks 
for each of the modified residues normalized against total ion counts across samples. In the case of HSA 
isolated from patients, the relative quantification of modified peptides was achieved by comparing the 
intensities of the MRM peaks for each of the modified residues. The K541 peptide, which was detected as 
the transition m/z 817 / m/z 517, was employed to normalise the L-MS/MS loading of tryptic peptides across 
samples as described previously.43 Data were analysed using Analyst software (Sciex). 
 
Quantification of CBZ and its Metabolites in Human Plasma. The validated LC-MS/MS method 
of Breton et al. for measuring CBZ, CBZE, CBZ-DHD, 2-OH-CBZ and 3-OH-CBZ in human plasma,23  
which used 2-Me-CBZ as internal standard, was adapted to assay single plasma samples from fifteen 
epilepsy patients on established CBZ therapy.  
Aliquots of stored plasma samples (300 L), and the calibration and quality control standards (300 
L), were deproteinized with acetone (300 μL). The supernatants were evaporated to dry residue in a 
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rotational vacuum concentrator, and reconstituted in acetone and water (1:1, v/v; 300 L). For the 
measurement of CBZ, CBZE and CBZ-DHD,  reconstituted supernatant (20 L) was injected onto a Zorbax 
C-8 pre-column and Eclipse XDB-C8 column (150  4.6 mm, 5µm) connected to a 1260 Infinity LC system 
(Agilent Technologies, Waldbronn, Germany) and 4000 Qtrap. Analytes were eluted at room temperature 
with an accelerated gradient program of acetonitrile (15% to 27% over 6 min; 27% to 32% over 5 min; 32% 
to 60% over 0.1 min; 60% for 2.9 min; 60% to 15% over 0.1 min; 15% for 2.4 min) in ammonium formate 
(2 mM, pH 3.8) at 1.0 mL/min. Instrument management and data processing were accomplished through 
Analyst 1.5.2 software (Sciex).  
For the measurement of 2OH-CBZ and 3OH-CBZ the reconstituted supernatant (100 μL) was 
centrifugally filtered at 450 g for 15 min at 4oC through a 0.45-μm hydrophilic PTFE filter plate (Merck 
Millipore, Watford, United Kingdom) to remove any remaining protein. The filtered supernatant (5 μL) was 
injected onto a 2.5 μM Xbridge BEH C18 VanGuard pre-column and Waters 2.5 μM Xbridge BEH C18 
column (2.1 mm x 150 mm; Waters Limited, Herts, United Kingdom) connected to an UltiMate 3000 HPLC 
system and 4000 QTrap. Analytes were eluted at 40 oC with a gradient program of acetonitrile (15% to 20% 
over 2 min; 20% to 25% over 2 min; 25% to 30% over 2 min; 30% to 60% over 2 min; 60% for 4 min; 60% 
to 15% over 0.1 min; and 15% for 6.9 min) in ammonium formate (2 mM, pH 3.8) at 0.2 mL/min. 
Instrument management was achieved using the Chromeleon 6.80 software (Dionex Corporation), linked 
using Dionex chromatography MS link version 2.7.0.2551 to Analyst 1.5.1 software. Data processing was 
accomplished through Analyst 1.5.1 software. The mass spectrometer settings are listed in Tables S3 and S4. 
MRM chromatograms for the analytical standards and 2-Me-CBZ are shown in Figures S2 and S3 of the 
Supporting Information. Representative multi-channel MRM chromatograms of the analytes in patients’ 
plasma are shown in Figures S4 and S5. The assay characteristics are summarized in Table S5. The absence 
of mass spectrometric (M+H parent ion) interference from the co-administered drugs (Table S6) and their 
known human plasma metabolites was established by literature searches for metabolite structures. 
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RESULTS 
Identification of the Microsomally Generated Reactive Metabolites of CBZ by Trapping as GSH 
Conjugates. As reported previously, two isomeric S-glutathione conjugates of CBZE (CBZE-SG1 and 
CBZE-SG2) were produced by incubation of CBZE with GSH25 and by incubation of CBZ, NADPH and 
GSH with human liver microsomes.29 These two conjugates were also produced in the incubations of CBZ 
with all three of the CYP enzymes. The microsomal incubations yielded an additional S-glutathione 
conjugate that was more polar, and consistently less abundant, than the isomeric metabolites derived from 
CBZE (Figure 1). By a process of elimination, the polar product was deduced to be a conjugate of an arene 
oxide that had not undergone the spontaneous dehydration and rearomatization customarily but not 
invariably associated with such thiol-addition products.45, 46 Bu et al. came to the same conclusion.29  A 
rearomatized GSH conjugate, at m/z 542, was not detected. The proportions of the three GSH conjugates 
generated by CYP3A4 and CYP2E1 were similar but a relatively higher proportion of the more polar 
singleton conjugate was produced by CYP2B6 (Table 1). All three P450 enzymes generated CBZE, 2OH-
CBZ and 3OH-CBZ (data not shown); whereas previously CYP2B6 and CYP2E1 were only known to 
catalyse the aromatic oxygenation of CBZ.47  
 
Characterisation of GSTP Modified by CBZE and Microsomally Generated Metabolites of CBZ. A 
CBZE adduct ( 252 amu) was identified at Cys47 of GSTP after the protein was incubated with synthetic 
10,11-epoxide (Figure 2). No adducts were detected at Cys14, Cys101 and Cys169. An [O]CBZ metabolite 
adduct was identified at Cys47 of GSTP that was isobarically consistent with the adduct formed when GSTP 
was reacted with synthetic CBZE. LC-MS/MS analysis of the tryptic digests of GSTP recovered from 
incubations of CBZ with human liver microsomes and Supersomes found the unmodified Cys47-containing 
45ASCLYGQLPK54 peptide (+2 ion at m/z 540.3). Modification of Cys47 by one or more [O]CBZ species 
(CBZE and/or one or more arene oxides; the adduct’s product ion spectrum does not enable a more precise 
chemical assignment) resulted in a doubly charged peptide ion at m/z 666.3 that eluted at 37 min, 
corresponding to a mass increase of 252 amu compared with the mass of the unmodified peptide. The 
sequence of the proposed [O]CBZ-modified peptide, 45ASC*LYGQLPK54, was confirmed by the peptide’s 
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product ion spectrum (Figure 2). An abundant ion at m/z 210.22 corresponded to isomeric fragments derived 
from synthetic CBZE, 2OH-CBZ and 3OH-CBZ, (Table S2), providing the first-line evidence of the 
adduct’s structure (Figure 2). The b3* ion (m/z 514.2) and the immonium ion derived from cysteine (m/z 
329.2), with an adduction of 252 amu, confirmed the addition of a [O]CBZ species to Cys47. Metabolism of 
CBZ to CBZE, 2OH-CBZ and 3OH-CBZ was confirmed in all of the human liver microsome incubations 
(data not shown); indicating the GSTP was probably exposed to arene oxides as well as to CBZE.48   
 
Characterisation of Modification of HSA by CBZE In Vitro. Following the incubation of HSA with 
synthetic CBZE a triply charged ion of m/z 717.7 was detected by LC-MS/MS, corresponding to an adduct 
derived from the tryptic peptide 145RHPYFYAPELLFFAK159 which was eluted at 70 min, with an additional 
mass of 252 amu. Abundant ions at m/z 180, 210, 236 and 253 correspond to fragments of the CBZE-
derived moiety of the adduct, the proposed structures of which are shown in Figure 3A. The b4* (+2 ion at 
m/z 403.7), b5* (+2 ion at m/z 477.2), b6* (+2 ion at m/z 558.7) and b7* (+2 ion at m/z 594.3) ions all have 
the mass addition of 252 amu, indicating [O]CBZ modification at His146 (Figure 3C). The spectrum for the 
unmodified peptide 145RHPYFYAPELLFFAK159 is available in the supplementary information as Figure S6. 
The His146 adduct was detected at all concentrations of CBZE and its relative abundance was positively 
correlated with increasing CBZE concentration (Figure 3D). The reaction between CBZE and HSA was first 
detected at 30 min and showed a positive trend towards greater relative abundance of adduct over time up to 
6 h (Figure 3D). A second triply charged ion, of m/z 573.9, was detected by LC-MS/MS at 60 min, 
corresponding to an adduct derived from the tryptic peptide 337RHPDYSVVLLLR348 with an additional mass 
of 252 amu (Figure S7). The b3* (+2 ion at m/z 378.7), b6* (+2 ion at m/z 504.7) and b7* (+2 ion at m/z 
554.2) ions all have the mass addition of 252 amu confirming addition of CBZE to His338. However, the 
His338 adduct was detected only at the highest molar ratio (5:1), and only after at least 3 h incubation. No 
CBZE adduct was detected at Cys34 of HSA. 
 
Characterisation of HSA Modified by Microsomally Generated Metabolites of CBZ. LC-MS/MS 
analysis of tryptic digests of HSA recovered from incubations with CBZ, NADPH and human liver 
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microsomes revealed [O]CBZ adducts at His146 (Figure 3E) and His338 that were indistinguishable from 
the adducts formed by the reaction of synthetic CBZE with HSA . There was also evidence for formation of 
CBZ adducts at His146 and His338, that is, a stable adduct produced by dehydration of a primary, 
dihydrohydroxyaryl, structure derived from an arene oxide. Figure 4A outlines the proposed mechanism for 
formation of an arene oxide adduct. A triply charged ion of m/z 711.7 detected at 63 min corresponded to an 
adduct of 145RHPYFYAPELLFFAK159 with an additional mass of 234 amu (Figure 4B), and the highlighted 
b and y fragments confirm the peptide sequence. A second triply charged ion detected at 49 min 
corresponded to an adduct of 337RHPDYSVVLLLR348 with an additional mass of 234 amu (Figure S8). 
 
Detection of CBZ-Derived Covalent Modifications of HSA in Epilepsy Patients. The clinical details of 
the fifteen patients who donated plasma samples are outlined in Table S1. Five subjects donated two plasma 
samples on separate visits. In total 20 plasma samples were analysed. Eight of the subjects were male and 
subjects were aged between 27 and 75, with the total daily dose of CBZ ranging from 200 mg to 1600 mg. 
The timings of the blood samples relative to the last dose of CBZ ranged from 70 to 580 min. The same 
[O]CBZ-modified His146 peptide, 145RH*PYFYAPELLFFAK159, was identified in all twenty plasma 
samples (Figure 5A), and its relative amounts are illustrated in Figure 5B. There was 16-fold variability 
between the lowest level of [O]CBZ-HSA adduct (subject C009) and the highest (subject C036). The 
relative plasma levels of [O]CBZ-HSA adduct, and the concentrations of CBZ, CBZE, 2OH-CBZ and 3OH-
CBZ, for each subject are available in Table S7. Correlations between the relative plasma levels of the 
[O]CBZ-modified HSA adduct and either drug dosage or the plasma concentrations of CBZ and its 
metabolites were undertaken. There was a moderate positive correlation between total daily CBZ dosage and 
the relative amount of the adduct (r2 = 0.39, p = 0.003). The strongest positive correlation was observed 
between CBZ plasma concentrations and the relative amount of adduct (r2 = 0.44, p = 0.002). Moderate 
positive correlations were also obtained between the relative amount of adduct and plasma CBZE 
concentrations (r2 = 0.35, p = 0.006) and between adduct levels and total plasma concentrations of the 
monoxygenated ([O]CBZ) metabolites (r2 = 0.36, p = 0.005). The weakest positive correlation was observed 
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between the combined plasma concentrations of 2OH- and 3OH-CBZ and the relative amount of adduct (r2 
= 0.26, p = 0.021) (Figure 6). 
 
Discussion 
This study demonstrates that microsomally generated electrophilic monoxygenated metabolites of CBZ are 
able to form covalent adducts with co-incubated soluble proteins - human GSTP and HSA - as well as with 
microsomal proteins15, 26, 27 and GSH (Scheme 2).25, 29 Reactive metabolite trapping by exogenous protein 
incubated with hepatic microsomes has been employed previously to identify the metabolites and 
characterize the protein adducts. Yukinaga et al. captured reactive intermediates of acetaminophen and 
raloxifene on Cys47 of human GSTP.49 Damsten et al. produced an adduct of N-acetyl-p-benzoquinone 
imine (NAPQI), the reactive metabolite of acetaminophen, on Cys34 of HSA by incubating whole plasma 
with the drug and rat liver microsomes.50  
 
Notwithstanding the chemical similarities of the synthetic CBZE-Cys47 and biogenic [O]CBZ-Cys47 
adducts, precise structural assignment of the latter was not achievable. When the reactive metabolites of 
CBZ produced by human liver microsomes were sampled with GSH, which enabled chromatographic 
resolution and a more confident identification of conjugate structures, confounding evidence of arene oxides 
as well as CBZE was obtained. The distinctive polar dihydrohydroxyCBZ-S-glutathione conjugate 
([O]CBZ-SG) resolved from the two CBZE derivatives was consistently less abundant but effectively 
precluded exclusive assignment of the [O]CBZ residue in the [O]CBZ-Cys47 adduct. However, LC-MS/MS 
analysis of the microsomal incubations failed to deliver supporting evidence of an arene oxide, in the form 
of a CBZ-S-glutathione conjugate generated by indicative rearomatization of an intermediate arene oxide 
derivative.45 An alternative, enzymic, approach to identifying a Cys47 adduct of an arene oxide was 
attempted. This was based on a presumed selectivity of benzylic and aromatic oxygenation of CBZ by P450 
enzymes. CYP3A4 is the predominant catalyst of 10,11-epoxidation in human liver microsomes, and 
otherwise only CYP2C8 was known to have this activity,51 whereas CYP2B6 is the most active aromatic 
hydroxylase.47 Incubations with Supersomes confirmed benzylic and aromatic oxygenation by CYP3A4 but 
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also revealed 10,11-epoxidation by CYP2E1 and CYP2B6. Nevertheless, comparison of the aromatic 
hydroxylase activity of the three P450 enzymes47 demonstrated positive association with the relative 
abundance of [O]CBZ-SG. It has been proposed that a reactive arene oxide intermediate is formed during 
hydroxylation of CBZ.15, 29  The greater formation of [O]CBZ-SG by CYP2B6, the isoform with greatest 
aromatic hydroxylase activity, is therefore consistent with the attribution of this conjugate to an arene oxide 
derivative. What appeared to be multiple [O]CBZ-SG and CBZ-SG adducts were detected in isolated rat 
hepatocytes.52 Several examples of stable dihydrohydroxyaryl-S-cysteinyl adducts of GSH,46, 53 other 
peptides46, 54 and proteins55 are known, indicating a structure of this type is less likely to rearomatize than 
might have been thought. Consequently it is a reasonable proposition that some of the [O]CBZ-S-Cys47 
adducts generated by human liver microsomes and Supersomes could have been derived from an arene 
oxide. 
 
Two adducts, at His146 and His338, were identified on incubation of CBZE and HSA. The His146 adduct 
was detectable at a low molar ratio (0.1:1, CBZE:HSA) after 30 min. Analogous (isobaric) [O]CBZ adducts 
at His146 and His338 were formed in microsomal incubations that also generated CBZE, 2OH-CBZ  and 
3OH-CBZ in the presence of HSA. Two additional adducts at His146 and His338, having the form of CBZ-
HSA, were found in the microsomal incubations of CBZ with HSA, and were assigned preliminarily to 
rearomatized derivatives of arene oxide adducts. If confirmed, this would represent the first chemical 
evidence of a CBZ arene oxide that has the ability to escape the microsomal microenvironment and modify 
soluble proteins. The His146 residue of HSA is located accessibly at the entrance to fatty acid binding site 1 
in subdomain IB.56 It reacts with diverse electrophilic species, including nevirapine metabolites,36 abacavir 
aldehyde (which also reacts with Cys34),37 and 12-prostaglandin J2, an ,-unsaturated ketone which 
functions as a regulator of inflammation.56 The (-)-enantiomer of the benzylic anti-diol epoxide of 
benzo[a]pyrene, which has certain structural similarities to CBZE, combines with HSA exclusively at Nτ of 
His146, retaining the dihydrohydroxyaryl structure.57 Although the Cys34 residue is conventionally 
regarded as the predominant site of HSA’s reactions with organic electrophiles,58 and is claimed to be more 
reactive than His146,59 no cysteine adducts were detected with either synthetic CBZE or [O]CBZ 
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metabolites. However, a number of other thiophilic compounds have also failed to react with Cys34 on 
HSA.56, 60  Commercial preparations of HSA often contain very high levels of mixed disulfides at Cys34,61 
potentially reducing its ability to react with electrophilic metabolites and leading to a failure to detect 
adducts. However, we have previously used the commercial HSA preparation selected for the present studies 
and readily detected adducts of 12-sulfoxynevirapine with Cys34 as well as with three histidine residues 
(including His146).36 Incubation of CBZE (final concentration, 0.8 mM) with fresh human plasma (37 OC, 3 
h), in which the fraction of sulfhydryl HSA is approximately 65%, generated adducts at His146 and His338 
but not at Cys34 (data not shown). It is therefore reasonable to attribute the absence of a detectable [O]CBZ 
adduct at Cys34 firstly to an inability of the epoxide to react with Cys34 rather than the absence of a 
nucleophilic (thiol/thiolate) side chain. While molecular dynamic simulations and docking studies have 
shown that the nucleophilic Cys34 thiolate is more accessible than the residue’s thiol form,62 the cavity lined 
by Cys34 is evidently too hindered to allow alkylative access by CBZE. Thus the side chain-selective 
adduction of GSTP and HSA by CBZE is characterized by a distinct duality: only occurring at cysteine (one 
of four; Figure 2B) in GSTP notwithstanding the protein has two histidines; and only at histidine (two of 
sixteen) in HSA notwithstanding the protein has a free cysteine of considerable nucleophilicity (Figure 3B). 
The selectivity of HSA’s haptenation is nonetheless highly compound-dependent; vinyl sulfones66 and 
abacavir aldehyde36 react at both Cys34 and His146.  
 
If the skin reactions associated with CBZ63, 64 are initiated by local protein haptenation, the haptenating 
species might be CBZE formed in the liver and delivered via the blood.23 However, protein-reactive 
metabolites of CBZ might also be produced locally. Cutaneous hypersensitivity to sulfonamides is similarly 
thought to be initiated by reactive drug metabolites.65 Intracellular protein adducts were detected when 
sulfamethoxazole or dapsone was incubated with human epidermal keratinocyte.66-68 Thus keratinocytes are 
able to bioactivate drugs and form drug-protein adducts which may represent the antigenic determinants for 
T cells. Exceptionally, bioactivation in keratinocytes was mediated by flavin-containing monoxygenases and 
peroxidases with limited involvement of P450.67, 68 Nevertheless human skin expresses multiple P450 
enzymes, including CYP3A4 and CYP2B6.69 Levels of CYP2B6 mRNA demonstrated the largest inter-
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individual variation, with CYP2B6 mRNA undetectable in some skin samples. Consequently metabolism of 
CBZ to reactive [O]CBZ species could occur in keratinocytes and there would be variation between patients 
in the production of [O]CBZ. Patients hypersensitive to CBZ may generate higher levels of [O]CBZ, 
overwhelming detoxification pathways and leading to keratinocyte death and hypersensitivity.    
 
For the first time [O]CBZ-modified protein was also detected in vivo, in patients prescribed standard CBZ 
therapy for epilepsy and without any indications of drug toxicity; including any indications of the 
neurotoxicity that has been associated with unusually high plasma concentrations of CBZE.70 The His146 
[O]CBZ-HSA adduct was identified in plasma samples from all of the 15 patients. There was both inter- and 
intra-patient variation in relative abundance of the adduct. Intra-patient variation in relative adduct 
abundance implies that the levels of [O]CBZ-HSA are likely to be dependent on parameters other than the 
size and timing of the dose. It is possible that all patients who receive CBZ therapy have [O]CBZ-HSA 
adducts in their circulation, irrespective of the imminence or presence of hypersensitivity, implying that 
other factors need also to be present to trigger a hypersensitivity reaction. Similar analyses conducted in 
patients receiving flucloxacillin therapy also identified parent drug- and metabolite-modified HSA in all 
(n=8) tolerant patients.40 These observations suggest that circulating drug-modified HSA alone might be 
generically insufficient to trigger hypersensitivity. Indeed, it is thought that a complex history of genetic and 
non-genetic patient factors determine the frequency and severity of drug hypersensitivity.  
 
CBZE-HSA adducts appeared detectably in vitro from 30 min and increased over time. The half-life of 
human albumin is 19 days, so it is expected that as patients commence CBZ therapy and titrate their dosages 
the levels of CBZE-HSA adduct will also increase. It is possible that hypersensitivity reactions to CBZ 
develop only when a critical threshold of adducts is exceeded. The time taken to reach that threshold could 
partially explain the two to six week delay between starting CBZ therapy and manifestation of 
hypersensitivity (Figure 3D).71 Cystic fibrosis patients receive multiple intravenous courses of antibiotics 
because of recurrent infections and are known to have a high incidence of piperacillin hypersensitivity (30-
50%).72 Studies in those patients demonstrated that as the plasma concentration of piperacillin is increased 
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the number of modified residues on albumin increases, generating a greater number of epitopes that could be 
recognised by the immune system.73 Similarly, the current study has identified a moderate but significant 
positive correlation (r2 = 0.39, p= 0.003) between relative abundance of [O]CBZ-HSA adduct and the 
dosage of CBZ. The strongest positive correlation was observed between relative abundance of [O]CBZ-
HSA and plasma CBZ concentrations. However, comparisons of the relative amount of [O]CBZ-HSA with 
plasma CBZE concentrations and the total concentrations of plasma [O]CBZ metabolites (CBZE, 2OH-CBZ 
and 3OH-CBZ) unexpectedly resulted in weaker positive correlations. In particular, the persistent circulation 
of CBZE in plasma suggested a greater positive correlation with epoxide concentration was to be expected. 
This finding implies the [O]CBZ-HSA adducts were not derived substantially from the intravascular 
reaction of CBZE with HSA. Admittedly the assay of plasma [O]CBZ-HSA adduct was only semi-
quantitative, because a CBZE-modified His146 tryptic peptide was not available for calibrated measurement 
of the adduct. [14C]CBZE is known to form covalent adducts with protein in human plasma ex vivo25 but 
apart from HSA, identified here, none of the modified proteins has been characterized. Therefore the present 
estimate of HSA’s adduction should be regarded as the minimum amount of [O]CBZ adducts formed. 
 
Synthetic CBZE and microsomal incubations of CBZ with HSA generated a second [O]CBZ-HSA adduct, at 
His338; which together with His146 and His242 is also adducted by the electrophilic sulfate of nevirapine.36 
However, no adduct other than the [O]CBZ-HSA at His146 was observed in patient samples because plasma 
levels of CBZE are unlikely to reach the molar ratios tested in vitro. The greatest concentration of CBZE 
observed in patients was 5.2 µg/mL (0.02 mM) and when compared with a typical plasma albumin 
concentration of 0.6 mM results in a molar ratio of 0.03:1 (CBZE:HSA) in comparison with molar ratios of 
0.1:1 to 5:1 (CBZE:HSA) tested in vitro. Although unlikely it is possible that a small fraction of patients 
form a second hapten during CBZ therapy. Russell et al. found a plasma CBZE concentration of 54 µg/mL 
(214 µM) after multiple medication overdose, including 17.8 g of CBZ, which would translate to molar 
ratios in the range of the in vitro incubations.70 The relationship between plasma levels of drug/metabolite-
protein adduct and susceptibility to hypersensitivity is poorly understood and warrants further investigation. 
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It has been suggested that CBZ hypersensitivity is mediated through a PI mechanism.10 However, all of the 
evidence is derived from experiments with isolated cells which cannot replicate the complexity of in vivo 
situations; where the extracellular drug concentrations might deviate substantially from those in tissues and 
the T-cells are not exposed to metabolites produced by cell types expressing P450 abundantly. Additionally, 
genetic variation in the activity of drug metabolism enzymes might lead to critical inter-individual 
differences between the levels of immunologically active metabolites.74 HLA-B*15:02 and HLA-A*31:01 
have both been associated with specific phenotypes of CBZ hypersensitivity reaction but both associations 
have very low positive predictive values,75 implying that factors other than HLA genotype are involved in 
pathogenesis of the hypersensitivity. The PI mechanism alone is unable to account for these findings. Future 
studies need to focus on assay systems that enable the generation of reactive metabolites and incorporate 
drug-modified peptides to determine their ability to elicit T-cell responses.73  
 
In conclusion, this study has provided the first chemical evidence for the microsomal production of [O]CBZ 
species that are able to escape the microsomal domain to react covalently with exogenous soluble proteins. 
If those species are equally able to escape from the endoplasmic reticulum of living cells they might 
haptenate numerous intracellular proteins. Most importantly, this study has demonstrated the presence of 
circulating [O]CBZ-modified HSA in patients who were receiving standard CBZ therapy. These findings 
have provided new insights into potential molecular mechanisms associated with toxicity of CBZ. Similar to 
the multiple protein adducts formed by nevirapine,36 the great variety of adducts formed by CBZ’s 
metabolites may account for the diversity of the organ toxicity of CBZ. Further studies are warranted to 
determine the biological effects of CBZ-modified proteins and peptides in in vitro models using well-
defined synthetic forms of the [O]CBZ and CBZ adducts discovered in this study. Definition of a 
quantitative relationship between CBZ antigens formed in tissues and the activation of tissue-specific T cells 
could pinpoint the causal metabolites involved in the rare but serious toxicity associated with CBZ in either 
skin or liver.  
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Table 1. Relative Proportions of the Three Isomeric Dihydrohydroxy-S-glutathione Conjugates 
Formed from CBZ by human liver microsomes and Supersomes  
enzymic 
preparation 
ratio of GSH adducts 
([O]CBZ-SG: CBZE-SG1: 
CBZE-SG2)a 
aromatic hydroxylase activity 
(pmol/nmol P450/min)b 
Human liver 
microsomes 
7.0 : 45.2 : 47.8 NA 
CYP3A4 10.3 : 42.5 : 47.2 72.5 
CYP2B6 25.5 : 34.5 : 40.0 186 
CYP2E1 13.1 : 40.6 : 46.3 38 
aRelative areas of peaks in m/z 560  431 MRM chromatograms acquired by LC-MS/MS (neutral loss of 
pyroglutamate from the protonated molecule). CBZE-SG1 and CBZE-SG2 are isomeric products of the 
reaction of CBZ 10,11-epoxide with GSH, identified by chromatographic and mass spectrometric 
comparisons with synthetic standards. [O]CBZ-SG is a GSH conjugate of unknown regiochemistry and 
stereochemistry assigned by process of elimination to a derivative of an arene oxide.  
bCombined C-2 and C-3 CBZ hydroxylase activities of human P450 enzymes taken from Pearce et al.47 
NA= not applicable. 
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Scheme Legends 
 
Scheme 1. Proposed Major Pathways of Bioactivation of CBZ in Humans and the Enzymes 
Catalysing the Reactionsa  
aThe P450 enzymes shown are those reported to be the principal catalysts of the biotransformations 
in question. However, it was found that CY2B6 and CYP2E1, as well as CYP3A4, catalyze the 
10,11-epoxidation of CBZ in vitro. The depiction of the 2,3-arene oxide as the sole product of 
aromatic epoxidation is purely representational; the number of arene oxides formed is unknown. 
Only protein adducts of the major reactive intermediates, namely the 10,11-epoxide and arene 
oxides, were considered during the present work. 
 
Scheme 2. Pathways for the bioactivation of CBZ and formation of [O]CBZ adducts with 
GSTP, GSH and HSA in vitro and in humansa 
aIn human plasma samples, only HSA modified by [O]CBZ species at His146 was detected. 
CBZE, carbamazepine 10,11-epoxide; HSA, human serum albumin; GSH, glutathione; GSTP, 
glutathione S-transferase pi; [O]CBZ, monoxygenated (carbamazepine) metabolites. 
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Scheme 1  
 
 
 
 
  
37 
 
Scheme 2 
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Figure Legends  
 
Figure 1. Isomeric GSH adducts of reactive monoxygenated metabolites of CBZ that were formed 
from CBZ incubated with HLM and Supersomes. The thioether metabolites produced by CYP2B6 
Supersomes are shown. CYP2B6 is the most active CBZ C-2 hydroxylase and the most active CBZ 
hydroxylase overall.45 CBZE-SG1 and CBZE-SG2 were assigned by comparison with standards 
prepared from synthetic CBZE. The assignment of the third product to an adduct of CBZ arene 
oxide was based on inference. 
 
Figure 2. Characterization of CBZE-GSTP adducts formed in vitro. The proposed general chemical 
structure and characteristic hapten fragment ion of the adduct formed by CBZE and GSTP (A); 
Ribbon diagram of human GSTP showing the locations of the four cysteine residues (red and 
yellow residues) [PyMol software (Schrödinger, Munich, Germany)]. Only Cys47 (red residue) was 
modified detectably, by synthetic CBZE in vitro and by monoxygenated CBZ metabolites (CBZE 
and/or CBZ arene oxide) in hepatic microsomal incubations. Cys14 and Cys101 are documented 
sites of alkylation by other electrophilic species,32,33 whereas Cys169 is outstandingly unreactive33 
(B); The top panel is a representative MS/MS spectrum of the unmodified GSTP peptide 
45ASCLYGQLPK54. The bottom panel is a representative MS/MS spectrum of the GSTP peptide 
45ASCLYGQLPK54 adducted at Cys47 by CBZE in direct incubation. A characteristic fragment ion 
derived from partial cleavage of the hapten is circled (C). 
 
 
Figure 3. Characterization of CBZE-HSA adducts formed in vitro. The proposed general chemical 
structure and characteristic hapten fragment ions of the adduct formed by CBZE and HSA (A); 
Ribbon diagram of HSA showing the locations of the two residues adducted by CBZE in vitro: 
His146 and His338 (blue residues) [PyMol software (Schrödinger, Munich, Germany)]. The single 
free cysteine residue, Cys34, is shown as a red residue. It was not modified detectably, either in 
vitro or in vivo (B); representative MS/MS spectrum of the peptide 145RHPYFYAPELLFFAK159 
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modified at His146 with CBZE; characteristic fragment ions derived from partial cleavage of the 
hapten are circled (C); the level of modification of the His146 peptide was concentration- and time-
dependent (drug/protein molar ratio 5:1) (D); Representative MS/MS spectrum of the peptide 
145RHPYFYAPELLFFAK159  modified at His146 with [O]CBZ from the CYP3A4 Supersomes 
incubation;  characteristic fragment ions derived from partial cleavage of the hapten are circled (E). 
 
Figure 4. Characterization of the adducts of CBZ arene oxide and HSA formed by microsomal 
incubations. Proposed reaction of arene oxide metabolite with His146 and His338 of HSA; showing 
rearomatization of the primary dihydrohydroxy adduct (A); representative MS/MS spectrum of the 
peptide 145RHPYFYAPELLFFAK159 modified at His146 by CBZ (considered to be the product of 
rearomatization of a dihydrohydroxy adduct of an arene oxide) (B)  
 
Figure 5. LC-MS/MS analysis of modified HSA peptides identified in patients prescribed CBZ 
therapy. Representative MS/MS spectrum of the albumin peptide 145RHPYFYAPELLFFAK159 
modified at His146 by [O]CBZ (A); Relative quantitation of [O]CBZ-HSA adducts in patients’ 
plasma samples. (b) denotes second plasma sample from the same patient at separate visit; data 
represents mean (n=3) and standard deviation (B). 
 
Figure 6. Correlations between relative amounts of [O]CBZ-HSA adduct in patients’ plasma 
samples and drug/metabolite concentrations. Total daily dosage (A); CBZ plasma concentration 
(B); CBZE plasma concentration (C); 2OH- and 3OH-CBZ plasma concentrations (D); total 
[O]CBZ plasma concentration (CBZE + 2OH-CBZ + 3OH-CBZ) (E).  
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Figure 1 
 
 
  
XIC of +MRM (10 pairs): 560.000/431.000 Da  from Sample 1 (CBZ_CYP2B6_GSH) of DataSET3.wiff (Turbo Spray) Max. 8733.3 cps.
2 4 6 8 10 12 14 16 18 20 22 24 26
Time, min
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
8733
In
te
n
s
it
y
, 
c
p
s
13.41
10.97[O]CBZ-SG 
CBZE-SG1 
CBZE-SG2 
CYP2B6 
41 
 
Cys14 
Cys101 
Cys169 
Cys47 
Figure 2 
A        B 
 
 
 
 
 
 
 
C
y2 
y5 y3 
y6 
y7 y8 
45
ASCLYGQLPK
54
 
(2+, 540.3, M=1078.6) 
b3* 
Cys 
immonium
+252 
y2 
y3 
y5 
y6 
y7 
45
ASC(CBZE)LYGQLPK
54
 
(2+, 666.3, M*=1330.6 
M=1078.6, Δm = 252) 
+2,y8 
42 
 
Cys34 His146 
His338 
Figure 3 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
43 
 
C 
 
 
+2,b5 
+2,b6 
+2,b7 
+2,y8 
+2,b7* 
+3, peptide+252 
b6 
b7 
+2, peptide 
y8 
y10 
b10 
b11 b12 y13 y9 
145
RH(+CBZE)PYFYAPELLFFAK
159
 
(3+, 717.7, M*=2151.1 
M=1899.0, Δm = 252.1) 
y9 
b6* b9 
b7* 
y10 
b10 b11 
y11 
y3 
y8 
y4 
+2,b4* 
+2,b5* +2,b6* 
+2,b7* 
+2,b6 
+2,b7 
unmodified 
modified 
44 
 
D 
 
 
 
 
0.0E+00
5.0E+06
1.0E+07
1.5E+07
2.0E+07
2.5E+07
0.5 1 3 6
N
o
rm
al
iz
e
d
 io
n
 c
o
u
n
ts
fo
r 
H
is
1
4
6
 a
d
d
u
ct
Time(h)
0.00E+00
4.00E+07
8.00E+07
1.20E+08
1.60E+08
0.1:1 1:1 5:1
N
o
rm
al
iz
e
d
 io
n
 c
o
u
n
ts
fo
r 
H
is
1
4
6
 a
d
d
u
ct
Drug protein molar ratio
45 
 
E 
 
 
  
145
RH(+CBZE)PYFYAPELLFFAK
159
 
(3+, 717.7, M*=2150.1 
M=1898.0, Δm = 252.1) 
+2,y8 
b7* 
+2,b5* 
+2,b7 
+2,b7* 
+3, peptide+252 
+2, peptide 
y4 
y1
b11 
b12 
y13 
+2,b6 
+2,b5 
b5 
+3, peptide 
b7 
y8 
y9 
+2,b6* 
+2,b7* 
+2,y9 
+2,b8 
46 
 
Figure 4 
 
A 
 
 
 
 
 
 
 
B 
 
145
RH(+CBZE)PYFYAPELLFFAK
159
 
(3+, 711.7, M*=2132.1 
M=1898.0, Δm = 234.1) 
y6 
+2,y8 
+2,b*2 
y9-H
2
O 
+2,b5 
y10 
b2 
+2,a6 
b6 
y8 
y4 
+3, peptide 
b5 
b*5/b6 
47 
  
 
47 
 
146RH(+CBZE)PYFYAPELLFFAK159 
(3+, 717.7, M*=2151.1 
M=1899.0, Δm =252.1) 
b5 
+2,b6 +2,b9 +2,b5 
y7 y6 
b7 y8 
+2,y8 
253.11 
Figure 5 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
0
2
4
6
8
10
12
14
16
18
20
R
e
la
ti
ve
 m
o
d
if
ic
at
io
n
 b
y 
[O
]C
B
Z 
(r
at
io
 t
o
 C
0
0
9
)
48 
  
 
48 
 
Figure 6 
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0
0
5
1 0
1 5
2 0
C B Z  d o s a g e  (m g )
R
e
la
ti
v
e
 A
d
d
u
c
t 
Q
u
a
n
ti
ta
ti
o
n
r
2
= 0 .3 9  (p = 0 .0 0 3 )
C B Z  D o s a g e
0 5 1 0 1 5
0
5
1 0
1 5
2 0
C B Z  P la s m a  L e v e ls
C B Z  le v e l ( g /m L )
R
e
la
ti
v
e
 A
d
d
u
c
t 
Q
u
a
n
ti
ta
ti
o
n
r
2
= 0 .4 4  (p = 0 .0 0 2 )
0 2 4 6
0
5
1 0
1 5
2 0
C B Z E  P la s m a  L e v e ls
C B Z E  le v e l ( g /m L )
R
e
la
ti
v
e
 A
d
d
u
c
t 
Q
u
a
n
ti
ta
ti
o
n
r
2
= 0 .3 5  (p = 0 .0 0 6 )
0 2 0 4 0 6 0 8 0 1 0 0
0
5
1 0
1 5
2 0
2 O H - &  3 O H -C B Z  P la s m a  L e v e ls
2 O H - &  3 O H -C B Z  le v e ls  (n g /m L )
R
e
la
ti
v
e
 A
d
d
u
c
t 
Q
u
a
n
ti
ti
a
ti
o
n
r
2
= 0 .2 6  (p = 0 .0 2 1 )
0 2 4 6
0
5
1 0
1 5
2 0
[O ]C B Z  P la s m a  L e v e ls
[O ]C B Z  le v e ls  ( g /m L )
R
e
la
ti
v
e
 A
d
d
u
c
t 
Q
u
a
n
ti
ta
ti
o
n
r
2
= 0 .3 6  (p = 0 .0 0 5 )
A B
DC
E
 
 
 
 
